Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Metabolomics - Global Strategic Business Report: Capitalize on an 11.7% CAGR to Secure the $7.1 Billion 2030 Market as Thermo Fisher, Agilent, Bruker, Waters, and Metabolon Reshape Competition

globenewswire.com
TMO Thermo Fisher Scientific is mentioned as a key participant in the global metabolomics market, which is projected to grow significantly. The article does not provide specific sentiment towards Thermo Fisher's performance or prospects within this market. A Agilent Technologies is listed as a company active in the metabolomics market. The article highlights the market's growth potential but does not offer specific sentiment on Agilent's position or performance within it. BRKR Bruker Corporation is identified as a company operating in the metabolomics market. The article focuses on the overall market growth and trends, without providing specific sentiment or performance indicators for Bruker. WAT Waters Corporation is mentioned as a participant in the metabolomics market. The article discusses the market's expansion and technological advancements but does not offer specific sentiment or analysis related to Waters.

Metabolomics - Global Strategic Business Report: Capitalize on an 11.7% CAGR to Secure the $7.1 Billion 2030 Market as Thermo Fisher, Agilent, Bruker, Waters, and Metabolon Reshape Competition Dublin, Nov. 03, 2026 (GLOBE NEWSWIRE) -- "Metabolomics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global metabolomics market was valued at US$3.7 billion in 2024 and is projected to reach US$7.1 billion by 2030, expanding at a compound annual growth rate (CAGR) of 11.7% during the forecast period. Growth is being supported by rising demand for precision medicine, advanced diagnostics, biomarker discovery, drug development, and personalized nutrition. The comprehensive market report also examines recent global tariff developments and their impact on metabolomics technologies, supply chains, sourcing strategies, and regional market prospects.

Metabolomics Market Trends and Growth Drivers

Metabolomics is becoming increasingly important in biological research, clinical diagnostics, and therapeutic development. By analyzing metabolite profiles, researchers can investigate cellular processes, identify disease-associated biomarkers, monitor therapeutic responses, and support individualized treatment strategies. Applications are expanding across cancer, cardiovascular disease, neurological disorders, metabolic conditions, and other areas requiring more precise diagnostic and treatment approaches.

Mass spectrometry, nuclear magnetic resonance, chromatography, and high-throughput analytical platforms continue to improve the accuracy, resolution, and speed of metabolite analysis. These advances are enabling laboratories to process increasingly complex biological samples and generate more comprehensive datasets. Bioinformatics, machine learning, cloud-based platforms, and open-access databases are also strengthening data interpretation and supporting collaboration among pharmaceutical companies, biotechnology firms, diagnostic laboratories, academic institutions, and contract research organizations.

The integration of metabolomics with genomics, proteomics, and transcriptomics is further expanding multi-omics research. This approach provides a broader view of biological systems and supports the identification of therapeutic targets, disease pathways, and patient-specific responses. As healthcare organizations and life sciences companies increase investment in precision medicine, metabolomics is expected to play a growing role in clinical research and product development.

Pharmaceutical, Healthcare, and Nutrition Applications

Pharmaceutical and biotechnology companies are adopting metabolomics to accelerate drug discovery, evaluate candidate compounds, optimize therapeutic efficacy, and reduce potential adverse effects. Metabolic signatures can help researchers stratify patients, improve clinical trial design, and identify populations most likely to respond to specific treatments.

Clinical laboratories are also exploring metabolomics for diagnostic and prognostic applications. Meanwhile, nutritional science and wellness programs are using metabolic data to assess dietary interventions and support personalized nutrition strategies. These expanding applications are creating commercial opportunities for analytical instrument manufacturers, software providers, research organizations, and specialized testing companies.

Market Segment and Regional Highlights

Report Scope

The report analyzes the global metabolomics market by value in U.S. dollars and provides annual sales forecasts from 2024 through 2030, supported by historical analysis from 2015 to 2023. Market coverage includes:

Tariff, Trade, and Economic Analysis

This edition incorporates current global trade and economic developments into the metabolomics market outlook. It assesses tariff negotiations involving more than 180 countries and examines potential consequences for scientific instruments, laboratory components, sourcing costs, supply continuity, and geographic realignment. Revised forecasts reflect economic uncertainty, tariff effects, and structural changes affecting globalization through 2030.

The analysis also reviews product and process innovation, emerging technologies, population and urbanization trends, regional economic indicators, and changes in competitive positioning. Updated global market share estimates for 2025 categorize participating companies by their relative competitive presence and provide additional context on major brands and specialized market participants.

Domain Expert Insights

The report tracks technological innovation, regulatory and trade developments, competitive activity, regional investment trends, and emerging applications across the metabolomics industry. Commentary from economists, trade specialists, and domain experts places market shifts in context and highlights potential revenue opportunities, supply chain risks, and strategic priorities for organizations operating in the sector.

Key Questions Addressed

Companies Featured

The report profiles 63 companies active in the global metabolomics market. Selected participants include AB Sciex LLC, Agilent Technologies, Inc., Biocrates Life Sciences AG, Bruker Corporation, Chenomx, Inc., GL Sciences Inc., Human Metabolome Technologies, Inc., LECO Corporation, Metabolon, Inc., PerkinElmer, Inc., Shimadzu Scientific Instruments, Thermo Fisher Scientific, Inc., and Waters Corporation.

Purchasers receive detailed global and regional market data, competitive intelligence, company profiles, strategic analysis, and complimentary report updates for one year. The findings are designed to support business planning, market entry assessment, product strategy, investment evaluation, and identification of emerging opportunities within the global metabolomics market.

Key Attributes:

For more information about this report visit https://www.researchandmarkets.com/r/a2xpfp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.